Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017199 · ClinicalTrials.gov registry record · Phase 2
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
A Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00017199 is a Phase 2 study that has completed, run by Ohio State University Comprehensive Cancer Center.
The verdict
NCT00017199, a Phase 2 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic neuroendocrine tumors.
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-04 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017199
The ClinicalTrials.gov registry entry for NCT00017199 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT00017199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017199 about?
NCT00017199 is a clinical study titled "PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic neuroendocrine tumors.
What is the current status of trial NCT00017199?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-04. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00017199?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00017199?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.